semaglutide cardiovascular outcomes news 2025 Oral and in Patients with Type 2 Diabetes Semaglutide cardiovascular outcomes align more

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide and tirzepatide, have emerged as transformative agents for type 2 diabetes and obesity through their potent effects on weight reduction, insulin sensitivity, and cardiovascular outcomes

M., Rosenstock, J., Tran, M

Long-term use of GLP-1 medications may lead to a higher incidence of osteomalacia

Doctor-supervised GLP-1 weight loss in Pasadena with FDA-approved medications

Both are considered chronic conditions that need to be managed over an individuals lifetime. GLP-1 for Diabetes If you are using a GLP-1 for diabetes management, do not stop the medication without speaking to your doctor first